bioAffinity Technologies, Inc. (NASDAQ:BIAF) has signed a nationwide federal healthcare distribution agreement with AvMEDICAL for CyPath Lung, giving the lung cancer diagnostic access to an established government sales and procurement network.
The agreement expands bioAffinity’s commercial reach without requiring it to build the federal distribution infrastructure independently, with AvMEDICAL’s existing sales force set to promote CyPath Lung to government healthcare customers, including U.S. Department of Veterans Affairs medical centers.
Key Investor Takeaways
- bioAffinity Technologies, Inc. (NASDAQ:BIAF) gains a new nationwide commercial channel for CyPath Lung across the federal healthcare market.
- AvMEDICAL will use its existing national sales team, government relationships and procurement expertise to market the test.
- AvMEDICAL’s status as a Service-Disabled Veteran-Owned Small Business and access to IDIQ contracts may simplify procurement by government healthcare systems.
- The agreement provides an additional route to commercial adoption but does not include revenue projections, minimum purchase commitments or other financial terms.
- CyPath Lung is designed to support assessment of lung cancer risk and indeterminate pulmonary nodules alongside imaging and other diagnostic tools.
Why BIAF Stock Is in Focus
The distribution agreement gives bioAffinity a direct route into a sizeable federal healthcare network through an established government supplier.
AvMEDICAL’s sales team will actively promote CyPath Lung to federal customers, including the VA, while the companies plan to develop co-branded marketing materials. Its government contracting experience and access to indefinite-delivery, indefinite-quantity contracts could reduce procurement barriers that might otherwise complicate adoption.
The VA represents a particularly relevant target market. Citing VA figures, bioAffinity said nearly 8,000 veterans are diagnosed with lung cancer annually and approximately 5,000 die from the disease each year.
CyPath Lung is performed by bioAffinity’s wholly owned Precision Pathology Laboratory Services subsidiary, which is CLIA-certified and CAP-accredited.
Why This Matters for Investors
For bioAffinity, the agreement primarily changes the commercial pathway rather than the underlying technology. AvMEDICAL provides an established sales organisation and procurement channel through which the company can pursue federal healthcare customers nationwide.
That could broaden CyPath Lung’s market exposure while allowing bioAffinity to leverage infrastructure already in place. The arrangement may be particularly significant if it leads to adoption across multiple VA medical centres or other federal healthcare agencies.
However, the announcement does not quantify expected sales, provide an implementation timetable or disclose guaranteed purchasing volumes. Investors therefore have limited information at this stage for assessing the agreement’s eventual financial contribution.
The clinical profile remains central to the commercial proposition. In a published trial involving high-risk patients with indeterminate lung nodules smaller than 20 millimetres, CyPath Lung demonstrated 92% sensitivity, 87% specificity, 88% accuracy and a 99% negative predictive value.
CyPath Lung is marketed as a Laboratory Developed Test and is not intended to serve as a standalone diagnostic. Its commercial adoption will therefore depend on how healthcare providers incorporate it alongside other clinical findings and diagnostic methods.
What to Watch Next
The next indication of commercial progress will be whether the AvMEDICAL partnership produces orders or broader adoption of CyPath Lung within VA medical centres and other federal healthcare agencies.
Investors can also watch for disclosure around purchasing volumes, new federal customers and the pace at which the expanded distribution network contributes to CyPath Lung testing activity and bioAffinity’s commercial performance.